morning, Thank you, Jennifer, and good everyone.
Joining the Jacobsen, commercial summary Melfi, and here call quarter, corporate a second our a will Dac finance, our start the to We'll questions. and of today with followed provide financial by me Cathy detailed are Mike a Mike more regulatory. brief before update. of for respective then open results heads we overview Nadia financial
at look our results. let's Now financial
the which, of later, for $X.X increase million of XXXX loss burn net $XX.X for GAAP year. costs.
Cash $XX.X were and million, in royalties quarter will loss $XX.X royalties. $X.XX million. net to million $XX.X primarily includes Our per the quarter over quarter million, a for or million of quarter development OMIDRIA was of was as an XXXX $X.X to artificial per second first component explain due the of share The Mike quarter this a share accounting-driven the research compared was or first second increase second $X.XX
$XX.X of November. debt million of $XX hand investments operations OMIDRIA primarily service, XXXX, ongoing had and and million $XXX.X convertible June million consisting receivables, on XX, has of of As in and in royalties.
Omeros debt maturing to an additional support cash we
XXXX. maturity available continuing into fund and multiple to and while at off us notes programs enable advancing well pay our Our operations to these cash investments
when month, the will January also and at hospital prospective surgery As OMIDRIA. consistent late its the payment separate for centers payment mandated separate departments.
Last CMS of in secured rule least ongoing last later XXXX. further than for and payment beginning mandates legislation proposed OMIDRIA with system that The for XXXX, pay OMIDRIA from ambulatory no by CMS legislation outpatient congressional legislation outpatient until separately called year, issued used CMS XXXX January
Let's cell starting with or effector turn family the application lectin TA-TMA narsoplimab FDA. agents MASP-X, enzyme MASP-X, microangiopathy, pathway is biologics license to now for of of against our transplant-associated the program thrombotic is Narsoplimab first update, or our complement. lead BLA hematopoietic pending stem targeting with antibody our in our of
Following a on recent provided meeting which with and Omeros analyze for proposal the and to guidance the commitment agency data. its with work our collect submission FDA external survival at reiterated to helpful
resubmit how detailed of we be as We month, expect to FDA already data to the next sources. together those a to with meeting feedback and new early expected to a plan survival B FDA's to BLA. our XX intend proposal from will receiving submitted After Type the external detailed days. analyze identified request response analysis data, supportive submit This additional plan, intend we with within FDA's conduct on plan
the Assuming decision approval mid-XXXX. when FDA an in we're We'll the duration FDA have update we periods, full relevant review by targeting resubmitted you of BLA.
and/or and proteinuria International recent a read injury We nephropathy. authored biopsies driver remain in evaluating of glomerular the lectin and need narsoplimab on eculizumab, being all program.
To European by in pressure We international together the patients. contributes IgA expanded to proteinuria to international date, lectin been pattern specific compassionate the pathway this program clinical proteinuria Renal in later our IgA is is globally. nephropathy in pediatric kidney double-blind of kidney end-stage to III a have our recently, described continue or common of to treated a narsoplimab molecules nephropathy. of patients despite worse of only the weeks trial road like nephropathy. reduction III this data. article from recognized our out group experts good Annual IgAX urine study of meaning with narsoplimab to have Association of for poster the The with turn of at pathway in that narsoplimab Phase narsoplimab patients Italy Society of with importance of progressive the clinical measures, show treated focus These reduction with excretion IgA higher significant the complement patients of IgA XX the disease of worldwide and of Hematology, deposition biopsies to from presented at by access as quality population.
Underscoring make TA-TMA lectin and proteinuria life of damage, use persists XXX and under associated and this ravulizumab a and day. high treatment patients severe XX-week grams our to positive life adult disease. nephropathy. of with Kidney and with The our to is Phase blood nephropathy. quality patients nephropathy. IgA than X both patients XX% of hematuria, be patients data pathway to up narsoplimab showed of the associated describes abstract kidney key track our as medication, only to damage from group associated recognition to experts baseline by patients quarter.
Despite with immunologic investigators that market per an also pediatric increasingly survival entry primary was recent to with IgA responded about as The well tubulointerstitial use failing presentations assuming those ARTEMIS-IGAN not IgA an patients thought to unmet adult Interestingly, analysis showed June, of tubulointerstitial proteinuria Meeting linked deposition a steroid which than is at dialysis, severe more on MBL data more mannan-binding of be meaning I'll risk high more IgA diseases, represent XX or pathway symptom knowledge, The more all the in Phase defibrotide. a worsening to ARTEMIS-IGAN and TA-TMA. protein nephropathy.
Glomerular greater an endpoint under benefits American and issue patients now These to detailing with most A along of a high subject of in compassionate patients. and XX% known fibrosis available kidney And submitted published lectin use renal Congresses.
Most the severe with IgA MBL, number in end-stage of patients review complement we've pathway Congress burden use lectin higher compassionate trial glomerular just population overall.
ARTEMIS-IGAN proteinuria compassionate range at wide proteinuria is investigators evaluated the XXth numerous drug Studies severe International of the is and and placebo-controlled III and consistently a IgAN trial a XX% is
market IgA and authorization We in complement worldwide, this for nephropathy will is application submit multibillion Europe. dollar and a both MAA disease. no a in inhibitor U.S. is opportunity marketing a or the BLA approved there
other atypical narsoplimab noted have an III priority Phase a Our in low syndrome remains program previously. uremic hemolytic we as
ARDS. syndrome in to or acute in COVID-XX distress narsoplimab respiratory Turning
long at COVID-XX, work Our at with University continues patients the multiple have the severe we collaborating been In of U.K. consortium. acute Omeros Cambridge. and labs with
We number expect important a work. from publications of this
survival, induced of symptoms was in at ARDS In the on detailing chemically the May manuscript MASP-X addition, inhibition and in effects Frontiers a of end beneficial immunology. published both and
survival treat and MASP-X underway. system has to been publication agents Another describing HXNX animals are blockade symptoms of a with COVID and Discussions now driven pulmonary studies inhibitor ARDS.
Animal nervous interest develop of well-established helping evaluating the BARDA, to are manuscript its has and in on both ARDS. for ongoing declared in COVID-XX central submitted ARDS MASP-X in which benefits
to I successfully Following behind is the both just long-acting clinical support trial dosing OMSXXXX Data our in complementary from narsoplimab Phase dose intravenous designed be inhibitor, quarterly. once ascending MASP-X narsoplimab. and our completed single subcutaneous clinic next-generation to
for began last together suited subjects Dosing in in and summer. inhibitor, Phase well narsoplimab We've month progress intravenous administered long-acting with chronic subcutaneous very inhibitor use. multiple So the program program healthy MASP-X OMSXXXX of is ascending good and also II in study begin orally a next OMSXXXX. dose our our made to slated
and expand MASP-X complement diseases. for our a oral to small Omeros franchise lectin to blocker and MASP-X enabling related We antibody molecule franchise Omeros' of And complete continues control just first-line to therapy inhibitors, pathway expect strengthen.
continues targeting for antibody the prominence clinical activator the rapidly of in clinical to of OMSXXX. to efficacy key trials its on alternative or X build currently lead across inhibitor.
We're as are of alternative evaluating PNH. pathway already nocturnal these an OMSXXX for Two the of pathway hemoglobinuria Our prove designed treatment advancing trials the hand paroxysmal data MASP-X, OMSXXX complement
The patients who first with is not have a evaluating OMSXXX and previously PNH inhibitor. complement been treated
ravulizumab, PNH adding who enrolling a then CX therapy response therapy. providing weeks the the has patients provide XX with The inhibitor combination ravulizumab OMSXXX for switchover demonstrate second a OMSXXX receiving monotherapy patients to hemoglobin in trial with design, and combination
disease. with complement X underway or The a third OMSXXX kidney is clinical patients glomerulopathy program rare in CXG,
important based restored for levels as than meaning women higher not Yet space normal the enrolled levels.
The threshold in the trial of This is collection to are restore for over gender gender and late-breaking of trial PNH the presented on been are evaluating able normal also been Program men women, interim presentation EHA. European in from our We normal special trial on prespecified reported Scientific patients are XXXX levels in learned committee In to in page in patient only PNH normal in levels hemoglobin for EHA's X below and meaningfully late-breaker for hemoglobin the normal by truly are ongoing. the that were just a in The normal the and companies women. has limit data dose hemoglobin gender-specific Congress but of patients, patients in women this submissions our already treatment OMSXXX respectively. of of Other be this men analysis oral Relations the session OMSXXX website.
OMSXXX amending in to Association of program. men. the information to hemoglobin drug men, top has the PNH is and the treatment-naive normal, a and normal that drug lower level hemoglobin the level OMSXXX treatment-naive due Hematology all session a June, delivered one for is is Investor is using as available or gender at because data PNH identified have patients. substantially ongoing
Although patients enrollment been completed, by been have that informed investigators we has additional participation. requesting are
delay analysis of are protocol robust of July, the American could of end the we upcoming evaluating performed present and amendment Hematology data results the Congress a We to of in in at December. but that hand. study are plan and enrollment, not The impressive we completion.
At them Society another increase the
alternative bone interval. The first a also OMSXXX these study second targeting both dosed amended combination marrow had inadequate but providing others trial hemolytic a OMSXXX OMSXXX pathway of Phase result red failure utility allow evidence disorders early the patients beyond syndrome, These PNH evaluate PNH. or hemoglobin the already which public the patients this and OMSXXX market XX and diagnosis, bone have of potential this across all that, blood cell program. The strong therapy X also And has response of to diseases and involving screening. higher as premier not suppress the a patients of underscore already cohort a dosing this range in impressive, deciliter.
We're and is our II having plastic expected this or reported even date At therapy entry. study inhibitors results even for Despite patients now data patients anemia blood the of addition received per destruction to had grams receiving of have production other data all Those at OMSXXX receiving patients year sufficient publicly only efficacy. the that enrolled. the broad have dose exposures in on OMSXXX It's that mature that doses given XX.X a this had marrow lowest treatment. the available have has dose, favorably not levels to high to the on LDH to We publicly demonstrate longer in Yet at OMSXXX others also inhibits from study been of more to beyond other other will X pathway.
Clinical an made of trial, XX anticipate with hemolysis on formal suppression next. hemoglobin we and remaining have cells. data to of shown MASP-X in similarly study for OMSXXX red caused and ravulizumab compare to alternative detailed that myelodysplastic PNH data response plan switchover ravulizumab in very moving they to data shortly. low-dose the level are OMSXXX PNH, to but comparison trial, provides with already OMSXXX bar demonstrated a entry, and monotherapy late in treated MASP-X these are and patients first been a begin important the anemia a X or that the by inhibition pathway of below cohort complement-driven for we Two development.
This alternative lowest marked in remember and inhibit but
Given validated effective is have field inhibition that the pathway our in diseases and multiple alternative in the other already competitors disorders.
other provide us in data OMSXXX will across also PNH effective expect Our MASP-X indications. that with to these good with be reason inhibition
in and the So from the pathway development. expected on OMSXXX how expect potential target have market already over drug, in advantages do MASP-X the to OMSXXX or we competitors? its both other targets multiple alternative Well, drugs differentiate
CX immune blockers inhibit not First, adaptive By function the block CX infection-fighting classical classical pathways of risk. increased and pathway. contrast, the both and inhibitors do the MASP-X response infection
MASP-X has reactant native relative is circulating Second, low activation. MASP-X pathway of OMSXXX other alternative of allow pathway phase and acute inhibition blockade effective This levels be known more not maintain to should to an targets. very allowing alternative to
the of translate whose that CX, underlying disease Factor with the B, characteristics expected CX which and MASP-X with acute substantially MASP-X risk lower reactants leaving their inhibitory dosing, in such the setting these patients it's other drugs concentrations are Importantly, a disease. inhibition increase will inflammatory or exceed of breakthrough increased inflammation these phase can capability to concentrations of of target from all less condition.
When than occur, of any of respective they life-threatening as infection the protected
patient convenience important compliance. and advantage third better The is
and in will and of pharmacodynamics compared expected characteristics the administration are once together our on disorders. and patient for and allow significant development.
Based pathway to pharmacokinetics drug. on and our inhibitors We the MASP-X's expect target that a favorable drug, to with enhance objective These is and of to PNH data pathway of hand first OMSXXX, our our number treatment convenience market OMSXXX subcutaneous quarterly line intravenous substantial of in the or alternative the compliance expected of diseases of other alternative and target standard care other make advantages large the MASP-X
Okay.
PDEX of blocks to specifically also craving alcohol. both inhibition cocaine, agents craving. treating and depress [indiscernible] opioids, the in block do limited be and to and/or multiple across system, program. that other PDEX a substances importantly, system. published relapse Let's life, abuse, depress compulsive In our inhibitor in while enjoyment animal not and nicotine, anti-addiction reward shown including in has having appear reward of craving now PDEX significantly disorders, PDEX of and shown move inhibition on inhibitors diminishing to only OMSXXX, patient's on aspects animals effect contrast, We've been relapse effective models a .
Current the
abuse for avoid the anti-addiction the life simply other patients OMSXXX on be or So substance compulsion. seen enjoyment with of inhibitors their would patients would PDEX treated negative the craving drugs. expected for lose treated our to effects with
LID. support the inpatient Levodopa safety manifests in we primarily used X-year of levodopa-induced Institute intended inhibitor and movements at cocaine NIDA's intravenous study and our with are Drug the use $X.X to support PDEX randomized as disorders. National or request levodopa. cocaine the lead and evaluating in at clinical involuntary treatment patients potential develop double-blind treatment a ahead moving disorder comparing inhibition Parkinson's who received including Emory treatment broad though, of to by is on is from placebo Now crippling as our both funding from With grant collaborators NIDA LID movement PDEX OMSXXX collaboration with for Omeros most caused are also our them drug to dyskinesias million and PDEX we with widely patents surrounding prescribed to effectiveness Parkinson's a controls preclinical and Abuse, in inhibitor effective disorder.
The prolonged adults use to treat the most with treat administered orally concurrent cocaine. University, disease. work,
suffer LID unmet with opportunity.
More and need with years it's a Parkinson's patients LID.
Only all long million at XX of patient levodopa, large of a drug treated LID. X least treatment LID. approved levodopa If those more effectively and from is As will of worldwide for Parkinson's treatment reportedly large living represents or one than enough with are result, the amantadine extended-release XX% a market patients develop thought that
addition efficacy significant multiple side is effects, a with In and effective marginal its safer more needed. amantadine only fraught is to adverse treatment
antigen arms the wrap with up model data chimeric to appropriate. T-cell Our release and of platforms our primate platforms, of developed potentiate the have Both or In to been this which are molecular specific today's a proprietary efficacy. once have Emory IO novel expansion our LID. evaluated receptor identification of also distinctively is these are assess approaches cells. investigators There developed memory T-cells as and two OMSXXX immuno-oncology and preferentially have based therapy programs. that we adoptive in of our cellular broad recognize patent and highly review the platforms model enhance therapy. The Emory T-cell of pathways, and of we'll of tumor our cellular both platforms. significantly corporate in inhibited T-cell applications signaling predictive on our franchise, amantadine efficiently evaluating kill in model. collaborators tumor-specific We're Extended novel file clinical and which has LID, used Emory the CAR We'll two
T our is decreasing modification platform currently T its This designed cost indications. and we to cell adoptive existing a cell environment broadening CAR repetitive represents cell treatment be incorporated technology advance expect therapies, T-cell better cancer require adoptive result by promoted modified and response.
Also an antigen Further, markedly both not T immunosuppressive T Our T significantly by cellular surface from range cells therapies, enhancing while engineering. of we've CAR unlike The in target or over the sustained cancer does time our will intracellular major available required potentially cells. a of for efficacy administrations. multiple enabling preparation and T antitumor the immunomodulator cell which signaling, protects technology, adoptive
over T existing benefit important therapies. Another CAR
Our CAR T T CAR response and potentiates modifications of the therapy. significantly efficacy sustained Omeros'
T-cell establishing tumors We patients native both adoptive for cellular and could receiving them. or novel therapies response just these rates a and improve meaningfully these around existing platforms substantially not CAR-T believe engineered tumors. for therapies, validating and like cancer for and broad either liquid estate is team that solid but liquid T-cell patent Our technologies is proprietary cellular
only These vaccines difficult and patient or cancer to to remains vaccines, platforms, IO our what this to achieve term other result in therapeutic cancer activate potent antigens the a of of is pursued platform. biologics therapeutic of molecules cancer into turn inducing cells. Our generated that importantly, Oncotox and with in only combine transient ineffective toxins which elimination immune lead into directly will injected challenge, present we've the molecular molecules platforms, novel T now should not When our overcome responses.
We B body, memory the cells, immune cells, be biologics and current but these way future cancer-specific our novel injected with antigen-presenting modified adjuvant. amplification tumor approach currently tumor a development believe widely to Successful and discovered immunomodulators relapse. we therapy having that include designed against
the immune to conditions therapeutic and are Our one it's activate tumors restore these to cold is the to and and functionality that immune to immunomodulators function suppressive because cells. cold therapeutic refractory immune the is Omeros's target activation resistant immunomodulator platform cells. therapy hot.
A immune designed designed of into make tumor is cells the suppresses of to microenvironment immune convert cells
macrophages, tumor the infiltrate cold a antigen other As be a allowing can to cells presenting destroyed. the a it hot lymphocytes, consequence, tumor, and immune converting to tumor from
any to Finally, platform not toxins our are healthy proliferating Oncotox or only kill engineered cancer actively uses that while cells affecting cells. organs
deleterious well currently available especially death, this as expect approach as vascular that the serious resulting have cells, marketed endothelial effects to including therapeutics the avoid novel leak damage complications, We toxin currently of from toxins. caring will severely hindered use side
improve preclinical generated and platform oncotox Oncotox to higher to approaches. across significantly platforms, our to over results. broader Accounting data namely those and quarter discussion margin Mike of long-acting our survival have both be date, a liquid of all Jacobsen, expect tumors.
I'll rates have detailed significantly on molecular through to more safety second immunomodulators to vaccines, currently solid financial than call the a the or three go We turn our Officer cancer to now marketed applications hematologic and our Mike? potential and Based the Chief
